Regenxbio (RGNX) Current Assets (2014 - 2026)
Regenxbio (RGNX) posted quarterly Current Assets of $281.3 million for Q4 2025, up 1.18% year-over-year from $278.0 million in Q4 2024, and down 15.27% quarter-over-quarter from $332.0 million in Q3 2025.
Regenxbio (RGNX) Current Assets (2014 - 2026) Analysis & Trends
Regenxbio's Current Assets history runs 12 years deep, the most recent figure standing at $281.3 million for Q4 2025.
- In Q4 2025, Current Assets rose 1.18% year-over-year to $281.3 million; the TTM figure through Dec 2025 stood at $281.3 million (up 1.18% YoY), while the FY2025 annual figure was $281.3 million, up 1.18% from the prior year.
- Current Assets for Q4 2025 stood at $281.3 million, down from $332.0 million in the prior quarter.
- The five-year high for Current Assets was $518.8 million in Q4 2021, with the low at $278.0 million in Q4 2024.
- The 5-year median for Current Assets is $384.0 million (2023), against an average of $386.6 million.
- The sharpest annual moves came in 2021 and 2025: Current Assets surged 47.42% in 2021, then decreased 20.78% in 2025.
- Regenxbio's Current Assets stood at $518.8 million in 2021, then dropped by 19.82% to $416.0 million in 2022, then declined by 19.47% to $335.0 million in 2023, then retreated by 17.01% to $278.0 million in 2024, then increased by 1.18% to $281.3 million in 2025.
- Business Quant data shows RGNX's Current Assets at $281.3 million in Q4 2025, $332.0 million in Q3 2025, and $373.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 236.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236.16 Mn |
| Dec 31, 2025 | 281.28 Mn |
| Sep 30, 2025 | 331.97 Mn |
| Jun 30, 2025 | 373.75 Mn |
| Mar 31, 2025 | 313.24 Mn |
| Dec 31, 2024 | 278.00 Mn |
| Sep 30, 2024 | 313.40 Mn |
| Jun 30, 2024 | 346.68 Mn |
| Mar 31, 2024 | 395.42 Mn |
| Dec 31, 2023 | 334.97 Mn |
| Sep 30, 2023 | 365.84 Mn |
| Jun 30, 2023 | 378.81 Mn |
| Mar 31, 2023 | 389.20 Mn |
| Dec 31, 2022 | 415.98 Mn |
| Sep 30, 2022 | 436.64 Mn |
| Jun 30, 2022 | 465.42 Mn |
| Mar 31, 2022 | 446.88 Mn |
| Dec 31, 2021 | 518.83 Mn |
| Sep 30, 2021 | 410.16 Mn |
| Jun 30, 2021 | 437.39 Mn |